[HTML][HTML] Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from …
B Sierra-Rodero, A Cruz-Bermúdez… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
B Sierra-Rodero, A Cruz-Bermúdez, E Nadal, Y Garitaonaindía, A Insa, J Mosquera…
Journal for immunotherapy of cancer, 2021•ncbi.nlm.nih.govBackground Pneumonitis (Pn) is one of the main immune-related adverse effects, having a
special importance in lung cancer, since they share affected tissue. Despite its clinical
relevance, Pn development remains an unpredictable treatment adverse effect, whose
mechanisms are mainly unknown, being even more obscure when it is associated to
chemoimmunotherapy. Methods In order to identify parameters associated to treatment
related Pn, we analyzed clinical variables and molecular parameters from 46 patients with …
special importance in lung cancer, since they share affected tissue. Despite its clinical
relevance, Pn development remains an unpredictable treatment adverse effect, whose
mechanisms are mainly unknown, being even more obscure when it is associated to
chemoimmunotherapy. Methods In order to identify parameters associated to treatment
related Pn, we analyzed clinical variables and molecular parameters from 46 patients with …
Abstract
Background
Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains an unpredictable treatment adverse effect, whose mechanisms are mainly unknown, being even more obscure when it is associated to chemoimmunotherapy.
Methods
In order to identify parameters associated to treatment related Pn, we analyzed clinical variables and molecular parameters from 46 patients with potentially resectable stage IIIA non-small-cell lung cancer treated with neoadjuvant chemoimmunotherapy included in the NADIM clinical trial (NCT03081689
ncbi.nlm.nih.gov